Excelsyn saw like-for-like sales increase 43.5% to $28m for its year ended 31 May. The company attributed the growth to an acceleration in volume demand and customer numbers for its pharma synthesis business and continuing growth in outsourcing of development and manufacturing services. Excelsyn ceo Ian Shott said the company's strategy, introduced in January, was delivering a significant upturn in business.
Excelsyn
Tuesday, 16 September 2008
Significant growth in Excelsyn sales
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment